Ajjai Alva

Also affiliated with Michigan United, Michigan Medicine, Ann Arbor VA Medical Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 38 papers. Top paper: “A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial”.

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

The Lancet(2021)10.1016/s0140-6736(21)00152-5

N/A

6.9DataRank · unranked

283 citations

Catherine M. Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y.C. Heng +15 more

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-2409

N/A

2.8DataRank · unranked

92 citations

Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, Seth P. Lerner, M. Scott Lucia +12 more

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer

New England Journal of Medicine(2024)10.1056/nejmoa2401497

N/A

2.4DataRank · unranked

64 citations

Catherine M. Tangen, Robert S. Svatek, Siamak Daneshmand, Kamal S. Pohar, Eila C. Skinner +15 more

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet(2023)10.1016/s0140-6736(23)00913-3

N/A

1.4DataRank · unranked

49 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +14 more

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)

European Urology(2023)10.1016/j.eururo.2023.06.014

N/A

0.650DataRank · unranked

20 citations

Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, M. Scott Lucia, David J. McConkey +12 more

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

Cancer(2020)10.1002/cncr.33067

N/A

0.538DataRank · unranked

35 citations

Michael R. Harrison, Peter H. O’Donnell, Ajjai Alva, Noah M. Hahn, Leonard J. Appleman +17 more

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

European Urology Oncology(2023)10.1016/j.euo.2023.11.014

N/A

0.442DataRank · unranked

18 citations

Fadi Taza, Navonil De Sarkar, Alok K. Tewari, Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz +32 more

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-001792

N/A

0DataRank · unranked

115 citations

Matthew D. Tucker, Ramy Sedhom, Eric Schwartz, Jason Zhu, Chester Kao +12 more

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study

Cancer(2021)10.1002/cncr.34057

N/A

0DataRank · unranked

86 citations

Nicholas Henderson, Marihella James, Divya Natesan, Dory Freeman, Amanda Nizam +31 more

Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes

British Journal of Urology(2021)10.1111/bju.15324

N/A

0DataRank · unranked

28 citations

Ali Raza Khaki, Leonidas Nikolaos Diamantopoulos, Lucía Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky +41 more

Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

International Journal of Molecular Sciences(2021)10.3390/ijms23010004

N/A

0DataRank · unranked

13 citations

Tadas Kasputis, Srinivas Nallandhighal, Sophia M. Abusamra, Amy Kasputis, Saloni Haruray +12 more

Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors

Urologic Oncology Seminars and Original Investigations(2021)10.1016/j.urolonc.2021.01.006

N/A

0DataRank · unranked

13 citations

Christopher Su, Miriam M. Hu, Jeremy M. G. Taylor, Stephanie Daignault‐Newton, Olesia Kellezi +13 more

Association of prior local therapy and outcomes with programmed‐death ligand‐1 inhibitors in advanced urothelial cancer

British Journal of Urology(2021)10.1111/bju.15603

N/A

0DataRank · unranked

5 citations

Rafee Talukder, Leonidas Nikolaos Diamantopoulos, Lucía Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky +42 more

Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4504

N/A

0DataRank · unranked

42 citations

Matthew I. Milowsky, Peter H. O’Donnell, Ajjai Alva, Marisa Kollmeier, Tracy L. Rose +15 more

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.270

N/A

0DataRank · unranked

9 citations

Catherine M. Tangen, Ian M. Thompson, Naomi B. Haas, Daniel J. George, Daniel Yick Chin Heng +15 more

Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5040

N/A

0DataRank · unranked

0 citations

Emily Nizialek, Jacob E. Berchuck, Panagiotis J. Vlachostergios, Ryan Ashkar, Alexandra Sokolova +14 more

Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.06.001

N/A

0DataRank · unranked

28 citations

Rafee Talukder, Genevieve Ihsiu Lin, Leonidas Nikolaos Diamantopoulos, Scott J. Dawsey, Shilpa Gupta +47 more

Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.08.006

N/A

0DataRank · unranked

9 citations

Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas Nikolaos Diamantopoulos, Scott J. Dawsey, Shilpa Gupta +49 more

Survival Prediction of Patients with Bladder Cancer after Cystectomy Based on Clinical, Radiomics, and Deep-Learning Descriptors

Cancers(2023)10.3390/cancers15174372

N/A

0DataRank · unranked

15 citations

Lubomir M. Hadjiiski, John Gormley, Heang‐Ping Chan, Elaine M. Caoili, Richard H. Cohan +4 more

EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.17_suppl.lba4500

N/A

0DataRank · unranked

39 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +15 more

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.536

N/A

0DataRank · unranked

5 citations

Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, M. Scott Lucia, David J. McConkey +12 more

Prognostic value and therapeutic implications of an integrative molecular subtype and immune content classifier in localized muscle-invasive bladder cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.530

N/A

0DataRank · unranked

1 citations

Brittney Cotta, Randy Vince, Srinivas Nallandhighal, Samuel D. Kaffenberger, Philip Palmbos +6 more

DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.129

N/A

0DataRank · unranked

0 citations

Richard E. Green, Joseph J. Park, Olesia Kellezi, Clara Hwang, Pedro C. Barata +15 more

Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy

Cancer Cell(2023)10.1016/j.ccell.2022.12.008

N/A

0DataRank · unranked

151 citations

Jae Eun Choi, Ilona Kryczek, Yilun Sun, Peng Liao, Shasha Li +22 more

Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0602

N/A

0DataRank · unranked

19 citations

David J. McConkey, Catherine M. Tangen, Joshua J. Meeks, Thomas W. Flaig, Xing Hua +12 more

SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4508

N/A

0DataRank · unranked

39 citations

Catherine M. Tangen, Robert S. Svatek, Siamak Daneshmand, Kamal S. Pohar, Eila C. Skinner +15 more

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0400

N/A

0DataRank · unranked

34 citations

Melissa A. Reimers, Chamila Perera, Wassim Abida, Jonathan Chou, Felix Y. Feng +17 more

Outcome Prediction Using Multi-Modal Information: Integrating Large Language Model-Extracted Clinical Information and Image Analysis

Cancers(2024)10.3390/cancers16132402

N/A

0DataRank · unranked

24 citations

Lubomir M. Hadjiiski, John Gormley, Heang‐Ping Chan, Elaine M. Caoili, Richard H. Cohan +6 more

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial

European Urology(2024)10.1016/j.eururo.2024.05.012

N/A

0DataRank · unranked

8 citations

Catherine M. Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell V. Meng +16 more

Evaluating the reliability of large language models for clinical data extraction in bladder cancer prognosis

Scientific Reports(2025)10.1038/s41598-025-27593-7

N/A

0DataRank · unranked

4 citations

Lubomir M. Hadjiiski, Grace Bruno, John Gormley, Heang‐Ping Chan, Elaine M. Caoili +6 more

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Cancer(2020)10.1002/cncr.33033

N/A

0DataRank · unranked

340 citations

Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi +26 more

Evaluating PSA dynamics for predicting androgen deprivation failure with a patient specific prostate cancer model

npj Systems Biology and Applications(2025)10.1038/s41540-025-00540-y

N/A

0DataRank · unranked

0 citations

Evan T. Keller, Tyler Robinson, Jinlu Dai, Alyssa Ghose, Ajjai Alva +3 more

Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer

European Urology(2020)10.1016/j.eururo.2020.06.033

N/A

0DataRank · unranked

79 citations

Pedro Isaacsson Velho, Roberto Nussenzveig, Jonathan Chipman, Víctor Sacristán Santos, Stephanie Erickson +9 more

Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer

Clinical Genitourinary Cancer(2020)10.1016/j.clgc.2019.10.019

N/A

0DataRank · unranked

8 citations

Stephanie Daignault‐Newton, Petros Grivas, Zachery R. Reichert, Maha Hussain, Kathleen A. Cooney +9 more

Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5028

N/A

0DataRank · unranked

4 citations

David J. McConkey, Catherine M. Tangen, Joshua J. Meeks, Thomas W. Flaig, Xing Hua +11 more

Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

Nature Medicine(2021)10.1038/s41591-020-1131-x

N/A

0DataRank · unranked

985 citations

Michael D. Green, Shasha Li, Yilun Sun, Sara N. Journey, Jae Eun Choi +35 more

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18 F-DCFPyL in Prostate Cancer Patients (OSPREY)

The Journal of Urology(2021)10.1097/ju.0000000000001698

N/A

0DataRank · unranked

381 citations

Michael A. Gorin, Steven P. Rowe, Peter R. Carroll, Frédéric Pouliot, Stephan Probst +12 more

Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance

Cancer Cell(2021)10.1016/j.ccell.2020.12.023

N/A

0DataRank · unranked

157 citations

Ilona Kryczek, Shasha Li, Michael D. Green, Alicia Ali, Reema Hamasha +21 more